JAGLX vs. XBI
Compare and contrast key facts about Janus Henderson Global Life Sciences Fund Class T (JAGLX) and SPDR S&P Biotech ETF (XBI).
JAGLX is an actively managed fund by Janus Henderson. It was launched on Dec 31, 1998. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.
Performance
JAGLX vs. XBI - Performance Comparison
Loading graphics...
JAGLX vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
JAGLX Janus Henderson Global Life Sciences Fund Class T | -3.75% | 24.72% | 8.50% | 7.41% | -2.79% | 6.66% | 25.52% | 29.12% | 4.05% | 22.13% |
XBI SPDR S&P Biotech ETF | 5.43% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 32.56% | -15.28% | 43.77% |
Returns By Period
In the year-to-date period, JAGLX achieves a -3.75% return, which is significantly lower than XBI's 5.43% return. Over the past 10 years, JAGLX has outperformed XBI with an annualized return of 11.55%, while XBI has yielded a comparatively lower 9.39% annualized return.
JAGLX
- 1D
- 3.08%
- 1M
- -5.56%
- YTD
- -3.75%
- 6M
- 11.82%
- 1Y
- 21.58%
- 3Y*
- 12.33%
- 5Y*
- 8.24%
- 10Y*
- 11.55%
XBI
- 1D
- 0.64%
- 1M
- 1.58%
- YTD
- 5.43%
- 6M
- 27.21%
- 1Y
- 65.07%
- 3Y*
- 19.25%
- 5Y*
- -1.16%
- 10Y*
- 9.39%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
JAGLX vs. XBI - Expense Ratio Comparison
JAGLX has a 0.92% expense ratio, which is higher than XBI's 0.35% expense ratio.
Return for Risk
JAGLX vs. XBI — Risk / Return Rank
JAGLX
XBI
JAGLX vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Janus Henderson Global Life Sciences Fund Class T (JAGLX) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| JAGLX | XBI | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.06 | 2.28 | -1.22 |
Sortino ratioReturn per unit of downside risk | 1.53 | 2.99 | -1.46 |
Omega ratioGain probability vs. loss probability | 1.20 | 1.38 | -0.18 |
Calmar ratioReturn relative to maximum drawdown | 1.78 | 4.41 | -2.63 |
Martin ratioReturn relative to average drawdown | 4.92 | 16.21 | -11.29 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| JAGLX | XBI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.06 | 2.28 | -1.22 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.53 | -0.04 | +0.56 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.66 | 0.29 | +0.37 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.58 | 0.36 | +0.22 |
Correlation
The correlation between JAGLX and XBI is 0.85, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
JAGLX vs. XBI - Dividend Comparison
JAGLX's dividend yield for the trailing twelve months is around 4.70%, more than XBI's 0.34% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
JAGLX Janus Henderson Global Life Sciences Fund Class T | 4.70% | 4.53% | 10.98% | 4.22% | 0.14% | 9.78% | 7.75% | 6.17% | 13.38% | 0.89% | 1.13% | 9.09% |
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Drawdowns
JAGLX vs. XBI - Drawdown Comparison
The maximum JAGLX drawdown since its inception was -58.96%, smaller than the maximum XBI drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for JAGLX and XBI.
Loading graphics...
Drawdown Indicators
| JAGLX | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -58.96% | -63.89% | +4.93% |
Max Drawdown (1Y)Largest decline over 1 year | -9.71% | -13.39% | +3.68% |
Max Drawdown (5Y)Largest decline over 5 years | -22.25% | -55.04% | +32.79% |
Max Drawdown (10Y)Largest decline over 10 years | -27.38% | -63.89% | +36.51% |
Current DrawdownCurrent decline from peak | -6.64% | -25.70% | +19.06% |
Average DrawdownAverage peak-to-trough decline | -17.51% | -20.91% | +3.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.63% | 3.65% | -0.02% |
Volatility
JAGLX vs. XBI - Volatility Comparison
The current volatility for Janus Henderson Global Life Sciences Fund Class T (JAGLX) is 5.99%, while SPDR S&P Biotech ETF (XBI) has a volatility of 11.31%. This indicates that JAGLX experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| JAGLX | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.99% | 11.31% | -5.32% |
Volatility (6M)Calculated over the trailing 6-month period | 10.63% | 19.25% | -8.62% |
Volatility (1Y)Calculated over the trailing 1-year period | 17.86% | 28.95% | -11.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 15.76% | 32.23% | -16.47% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 17.45% | 32.15% | -14.70% |